Safety of sequential immune checkpoint inhibitors after prior immune therapy

• DOI: 10.1007/s00432-022-04137-4
• Publication Date: 2022-06-21T14:09:42Z
• Authors: Muhammad Awidi; Brendan Connell; Delaney Johnson; Isabel Craven; Rojer Ranjit; Brigitte Gil; Natalie Dal’Bo; Lewena Maher; Seanna Reilly Daves; Stephanie McDonald; Krishna S. Gunturu
• Keywords: Tolerability; Regimen; Hematology

The use of immune checkpoint inhibitors (ICI) has transformed cancer treatment. Subsequent ICI become increasingly common following disease progression. We aim to evaluate the safety and tolerability sequential treatment modality.Retrospective review confirmed carcinoma from January 2014 December 2018. Patients were categorized into "initial arm" "sequential defined as patients receiving single, dual or chemo-immunotherapy an initial regimen. Primary outcome was development a new recurrent related adverse event (irAE) during therapy. Secondary outcomes number cycles prior irAE grade irAE.A total 483 received timeframe. Of those, 22 ICI. diagnoses included ten lung cancer, seven melanoma, four renal cell one bladder cancer. 16 single agent ICI, three patient chemotherapy-immunotherapy two after Four developed same on A higher proportion experienced 3 in arm compared (p = 0.03). No statistical difference found between either groups 0.5).Our data shows overall sequencing when close monitoring employed.